Wedbush set a $11.00 target price on Sangamo Therapeutics (NASDAQ:SGMO) in a research note issued to investors on Tuesday, TipRanks reports. The brokerage currently has a hold rating on the biopharmaceutical company’s stock. Wedbush also issued estimates for Sangamo Therapeutics’ Q2 2019 earnings at ($0.18) EPS, Q3 2019 earnings at ($0.18) EPS, Q4 2019 earnings at ($0.17) EPS, FY2019 earnings at ($0.92) EPS, FY2020 earnings at ($1.17) EPS, FY2021 earnings at ($1.38) EPS, FY2022 earnings at ($1.45) EPS and FY2023 earnings at ($1.51) EPS.
Other equities analysts have also issued research reports about the company. ValuEngine lowered Sangamo Therapeutics from a hold rating to a sell rating in a research note on Sunday, February 10th. BidaskClub raised Sangamo Therapeutics from a buy rating to a strong-buy rating in a research note on Saturday, February 2nd. Finally, Zacks Investment Research lowered Sangamo Therapeutics from a hold rating to a sell rating in a research note on Friday, January 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $16.00.
SGMO opened at $10.19 on Tuesday. Sangamo Therapeutics has a 12-month low of $6.26 and a 12-month high of $19.25. The company has a current ratio of 3.98, a quick ratio of 3.98 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.18 billion, a P/E ratio of -14.56 and a beta of 2.89.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.14). Sangamo Therapeutics had a negative return on equity of 24.67% and a negative net margin of 113.03%. The firm had revenue of $8.07 million for the quarter, compared to analyst estimates of $27.21 million. Equities analysts forecast that Sangamo Therapeutics will post -1.33 earnings per share for the current year.
In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of the stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $10.00, for a total value of $50,000.00. Following the sale, the chief financial officer now owns 30,512 shares of the company’s stock, valued at approximately $305,120. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 20,000 shares of company stock worth $210,550 in the last ninety days. 1.30% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the business. Advisor Group Inc. raised its position in shares of Sangamo Therapeutics by 222.8% during the 1st quarter. Advisor Group Inc. now owns 4,680 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 3,230 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Sangamo Therapeutics by 29.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,787 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 1,552 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in shares of Sangamo Therapeutics during the 4th quarter worth about $102,000. Pearl River Capital LLC acquired a new stake in shares of Sangamo Therapeutics during the 1st quarter worth about $94,000. Finally, Merriman Wealth Management LLC acquired a new stake in shares of Sangamo Therapeutics during the 4th quarter worth about $119,000. 54.92% of the stock is currently owned by institutional investors.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Read More: What is a Buy-Side Analyst?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.